IBM's 2028 Quantum Bet: Real Business or Hope Discounting the Near Term?

IBM's near-term business is testing investor patience on the quantum story

IBM is asking investors to consider a future trillion dollars of value in quantum while its current financial profile still looks like a mature software and services business working through a soft patch. In Q2, IBM generated $17.16 billion in revenue and $2.93 adjusted EPS, with revenue growth at 1% year over year. That is not a breakdown, but it is not the kind of near-term growth profile that makes valuation easy.

The 2028 promise has to be separated from the earnings miss

The stock's sharp post-earnings reset changed the mood, but it also raised the risk that investors anchor too tightly on recent pain. Management tried to steady that narrative by reaffirming 4% to 5% constant currency revenue growth and about $1 billion of higher free cash flow for the full year. That supports the case for a temporary setback more than a transformed business.

The cleaner way to frame the situation is to value IBM's current enterprise engine on near-term execution, then treat quantum as a longer-dated option rather than current earnings power.

Why 2028 is plausible, but not yet commercially proven

After the earnings reset, 2028 looks less like a fantasy deadline and more like the first checkpoint where investors can begin to separate real commercial traction from narrative momentum.

Technical progress matters, but it is not the same as revenue scale

IBM and Algorithmiq demonstrated quantum advantage by solving certain problems more efficiently than leading classical systems while also verifying the results. That does not prove broad commercialization. It does, however, show a possible starting point: quantum may matter first in narrow problems where even a modest efficiency gain changes what is computationally feasible.

That is why Krishna's expectation of measurable impact on revenue and earnings by 2028 or 2029 is plausible rather than purely speculative. The likely path is not instant replacement of classical computing. It is incremental monetization in high-value domains such as batteries, advanced materials, fusion energy, and medicine.

IBM is investing across more than one hardware path

IBM's recent moves suggest it is trying to shape the commercialization path, not just celebrate lab milestones. The company has outlined plans for a standalone quantum chip foundry, which points to a broader ambition in the hardware and fabrication stack. The proposed HRL Laboratories deal matters for a similar reason: IBM said it adds electron spin qubit expertise and described the move as a second pillar of its quantum effort. That reduces the risk of putting the entire strategy behind one hardware approach.

The key question is not whether quantum can win somewhere once. It is whether those wins build into repeatable demand, then into broader infrastructure demand, and eventually into results large enough to matter to IBM's consolidated financials.

The valuation mistake is blending two different risk profiles

The recent earnings shock changed sentiment, but it should also have changed the framework.

Near-term execution and long-term optionality should be judged differently

IBM is not one business with one discount rate. The current enterprise engine is a near-term execution story; quantum is a long-dated option story.

The near term still deserves scrutiny, but not panic. Management argues some demand was delayed rather than destroyed, with about 40% of postponed deals closed within three to four weeks. That does not erase the lowered full-year growth forecast or the fact that IBM missed after estimates had already been trimmed. It does suggest the more useful reaction is tighter monitoring of demand conversion, not a blanket reset of the whole portfolio.

Quantum deserves a different treatment: less emotional discounting, more option-style thinking. Technical milestones like quantum advantage do not justify an immediate earnings re-rating, and measurable impact by 2028 or 2029 is still a forecast, not booked business. What they do justify is recognizing that the optionality has value even while it remains unrealized in reported results.

What evidence would make IBM's 2028 quantum case easier to support

The debate is no longer whether quantum is real. It is what evidence would make the investment case clearer.

A narrower watchlist for the next few years

Bulls should stop treating technical milestones as proof of economic capture. IBM and Algorithmiq did show quantum advantage, and Krishna says quantum could begin to affect revenue and earnings by 2028 or 2029. But that remains a forecast. The next checks are operational.

Watch for: - Revenue with receipts: quantum-linked income that shows up alongside accelerate our revenue growth and profitability and the stated push to widen pre-tax margin through higher productivity. If the story is progressing, investors should eventually see quantum-linked revenue rather than only productivity language. - Customer traction, not just lab traction: clearer use-case wins in areas such as batteries, materials, or drug discovery, and evidence that the second pillar from HRL is sharpening IBM's roadmap rather than simply adding prestige. - Delay quality in the core business: Krishna says postponed deals were deferred rather than canceled, with about 40% closed within three to four weeks. The next few quarters should show whether that pattern holds.

The clearest invalidation signals are simple: enterprise delays broaden, quantum remains technical without monetization, or the 2028 or 2029 window slips. A disciplined stance is to value IBM on the mature business first, then credit quantum only as evidence accumulates.